# To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

> **NCT00150176** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 831 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Asenapine - Open Label
- **DRUG:** Placebo - Double Blind
- **DRUG:** Asenapine - Double Blind

## Key facts

- **NCT ID:** NCT00150176
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-07
- **Target enrollment:** 831 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150176, "To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00150176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*